CMAB Biopharma Inc., a BioBAY Park, Suzhou, China-based full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products, completed a US$38m series A financing.
The round was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium.
Led by President Mr. Liang Qibin, CMAB is a flexible full-service CDMO dedicated to providing bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. The company will provide services for development of manufacturing processes, analytical methods, formulation, and manufacture of biologic drug substances and drug products. Initial services will generate pre-clinical and early-stage clinical (Phase I/II) products for Chinese and global clients. CMAB’s manufacturing follows global Good Manufacturing Practices (GMP) standards, including those of the China Food & Drug Administration, US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards.
Currently, CMAB has 65 employees and plans to expand to 180 staff within one year.